Vitamin D, taxotere combination promising for advanced prostate cancer


Results of a new study strongly suggest that DN-101, a new high-dose calcitriol pill designed specifically as a cancer therapy, given in combination with docetaxel (Taxotere) extends the lives of men with advanced prostate cancer. And, the toxicity o

(I-Newswire) May 22, 2005 - "The data strongly suggest that DN-101, given in combination with docetaxel, will provide a substantial survival benefit to prostate cancer patients without adding toxicity," said Tomasz Beer, M.D., national leader of the clinical trial and director of the Prostate Cancer Program in the Oregon Health & Science University Cancer Institute. "While we've known about the anti-tumor potential of vitamin D, toxicity has been a significant issue to be overcome in making it a successful part of prostate cancer therapy."

Results from the study, the AIPC Study of Calcitriol Enhancing Taxotere (ASCENT), were presented on Sunday, May 15, at the 41st annual meeting of the American Society for Clinical Oncologists in Orlando, Fla. Christopher Ryan, M.D, member of the OHSU Cancer Institute, served as principal investigator at the OHSU study site. The study was supported by Novacea Inc., maker of DN-101, in collaboration with Sanofi-Aventis, maker of Taxotere.

ASCENT is a randomized, double-blinded, placebo-controlled clinical trial to evaluate DN-101 in combination with docetaxel for advanced prostate cancer research subjects who are no longer responding to hormonal therapy, a condition known as androgen-independent prostate cancer (AIPC). Two hundred fifty subjects participated in the study at 48 sites between September 2002 and January 2004.

Researchers estimate that subjects receiving DN-101 in combination with docetaxel survive 7.1 months longer than those who received docetaxel alone. The U.S. Food and Drug Administration approved docetaxel as the standard of care for AIPC last year.

Survival benefits of the drug combination were confirmed by a prospectively planned multivariate analysis. The analysis showed ASCENT's survival data to be statistically significant (p=0.035) with a hazard ratio of 0.67. This means that subjects receiving DN-101 in combination with docetaxel appear to have a 49 percent increase in survival versus subjects taking docetaxel alone.

"The overall goal of the study was to confirm results from a small phase II OHSU study and to determine if this combination should be developed as a new treatment for advanced prostate cancer," Beer said. "Our results demonstrate that DN-101 has the potential to improve outcomes for patients and that moving forward with development of the drug is the right thing to do."

Overall survival was the secondary endpoint of ASCENT. The study's primary endpoint was a 50 percent or more reduction of prostate specific antigen (PSA), a protein made only by prostate cells. Certain prostate conditions, including prostate cancer, are associated with high levels of PSA in the blood.

Overall PSA responses occurred more frequently in subjects receiving the DN-101 plus docetaxel combination (63 percent) versus docetaxel alone (52 percent). While the difference between the two arms did not reach statistical significance (p=0.07), the combination results represent an historically strong PSA response. Six months into the study, 58 percent of DN-101 and 49 percent of placebo-treated patients had experienced a PSA response.

"During the past year, new work done by colleagues in the field has shown that only about half of survival can be explained by changes in PSA," Beer said. "Though PSA remains important, it has turned out to be a middle-of-the-road predictor of survival."

DN-101 works by producing much higher blood levels of calcitriol (1,25 dihydroxycholecalciferol) than the body can produce from dietary vitamin D or vitamin D supplements. In high doses, 1,25 dihydroxycholecalciferol enhances many commonly used chemotherapeutic agents, producing anti-tumor activity in laboratory and animal models.

Beer and W. David Henner, M.D., are the inventors of DN-101. Henner is a former OHSU faculty member. Henner has joined Novacea Inc., the company formed to develop DN-101, to play a key role in the development of the drug.

Beer and OHSU have a significant financial interest in Novacea Inc., a company that may have a commercial interest in the results of this research and technology. This potential conflict was reviewed and a management plan approved by the OHSU Conflict of Interest in Research Committee, and the Integrity Program Oversight Council was implemented.

ASCO Abstract No. 4516: "Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC)"

To access all OHSU news releases, visit http://www.ohsu.edu/news

Contact: Rachel MacKnight
macknigh@ohsu.edu
503-494-8231
Oregon Health & Science University
http://www.ohsu.edu



Company Contact Information




Archive

May 22, 2005

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.


Related Releases

Relish The Interesting Stories Of Amar Chitra Katha At Unbelievable Price On Infibeam

Get the best collection of Indian stories published by Amar Chitra Katha at infibeam, an online shopping website at an unbelievable additional 15% off.

Lamb of God Partners with Specticast for Worldwide Theatrical Distribution of "As The Palaces Burn" Documentary Film

As The Palaces Burn is a film about metal icons Lamb of God, the zealous passion of their fan base, and the gut-wrenching manslaughter trial of lead singer Randy Blythe.

Mervik Haums Publishes Free Infographic To Explain Affiliate Marketing

An Infographic is by far the best way to demonstrate any idea or marketing plan. As it is a visual representation of information, data and knowledge, the viewer get a very clear idea about whatever the graphic is built for.

86.7% Of People Think It Is A Good Time To Be Investing In Adelaide Property

Adelaide Finance Brokers Urbantech Group recently ran a survey on their website. They asked the simple question: "Do you think it is a good time to be i

The Metro Joins The Hunt For Santa With Ted Burns

Ted Burns, the host of Third Degree, is searching for Santa, also known as the Yuletide Yobbo. And now he's got the support of the Metro, the UK's leading free newspaper.

Latest 10 Headlines

eZ-Xpo Offers Free Services to Christian Business Network and Non-Profit Organizations

eZ-Xpo announced a new offer for Christian Business Networks and non-profit organization with free access to its Christian Business Network Marketplace starting Easter weekend, April 20, 2014.

Tampa Hair Salon, Finest Beauty And Hair Salon In Tampa

Full Service Beauty and hair salon in Tampa, Fl. We specialize in Hair Designs, Extensions, Keratin Treatment, Spray Tanning and much more. For those looking for the top Tampa beauty parlor, you've found the right place.

Post-NAB 2014 Editors' Lounge To Feature The Latest From Avid

Product designers and managers are coming from the Massachusetts office to give demonstrations throughout the evening and will be available to answer questions and discuss Avid's strategy and vision for the future

The Life-Saving Oxy Gulls

Oxy Gulls is a compact and portable oxygen device for those who need immediate oxygen in order to survive.

Healthy Eating For Ladies

Venus Factor was discovered to work in unison with girls mainly because it activates the course of action that burns fat within your body, as opposed to other nutritional diets.

Nous Infosystems and SmartBear Software Enter Strategic Partnership

Nous SmartBear Partnership to Establish Offshore Center of Excellence (CoE) in Bangalore Expanding Global Reach of SmartBear's Automated Testing Tools

CIS Quoted in Industry Publication on the Push to Delay New Medicaid Generic Reimbursement Rates

CIS expert Sharon H. Greeson, R.Ph provided insight on CMS' expectation that states implement a new formula mandated under the PPACA that will significantly trim Medicaid reimbursement rates for generic drugs.

Designs2HTML Delivers 100% Pixel-perfect WP Themes Starting at $129

Designs2HTML has been indulged in delivering finest markup conversions for websites belonging to both, small-scale enterprise owners as well as the huge industry giants.

Phytoceramides Review Answers Consumers' Questions About Phytoceramide Anti-Aging Pills

PhytoceramidesReview.net informs and helps consumers worldwide by posting reviews and answers concerning one of the most talked about skin rejuvenating supplements - the phytoceramide capsules.

A Soft Foam Pad, The Mounty Pad

A Soft Foam Pad, The Mounty Pad protects from damage that occurs when two objects come in contact with each other.

Helpful Articles

Increase Website Traffic By Using Press Releases
Write A Press Release For Big Time News
Get Backlinks From Press Releases
How To Write A Press Release Quick And Easy
Choosing A Press Release Service
Writing A News Press Release
Get More Traffic From Press Releases
Is A Press Release Service Worth It?
Effective Press Release Distribution
Create a Successful Online Press Release
Submit A Press Release and Get More Traffic
How To Write A Press Release
Check This Before You Send A Press Release
Using A Press Release Service For Your News Release

Our Services:

Submit Your Free Press Release Now.

Open Now:
Online Classified Ads at I-Newswire.com
Job Search Engine at I-Newswire.com
Car Search Engine at I-Newswire.com
Real Estate Search at I-Newswire.com
Website News Releases, Announcements and Updates

Other Cool Sites:
Breaking and Latest Automotive News
Learn the secrets on how to become an alpha male and how to meet girls on facebook at Dating-To-Mating.com. Check out the best spinner and instant article factory for your content writing needs.